Oxcarbazepine Suspension
Product Images NDC 10135-798

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 10135-798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcar-12 (Oxcar 12)

A Kaplan-Meier survival curve graph showing time to exit (days) for two treatment groups labeled as HIGH and LOW. The y-axis represents the exit rate ranging from 0 to 1.0. A log-rank test p-value of 0.0001 is noted, indicating statistical comparison between the groups.*

FDA Label Image

Oxcar-14 (Oxcar 14)

An illustration showing an oral suspension dosing cup, designed for measuring liquid medication doses accurately. The cup is cylindrical with measurement markings and a small spout opening at the top center.*

FDA Label Image

Oxcar-15 (Oxcar 15)

The image shows a pharmaceutical suspension bottle of Oxcarbazepine, an oral medication. The bottle is capped with a white screw top and contains a liquid suspension form of the drug. No label text or additional identifying information is visible on the bottle.*

FDA Label Image

Oxcar-16 (Oxcar 16)

An instructional diagram of an oral dosing syringe used to measure liquid medication. The syringe includes a labeled barrel marked in milliliters up to 10 mL, and a plunger for drawing and dispensing the suspension. The diagram labels these two parts clearly as 'Barrel' and 'Plunger.'*

FDA Label Image

Oxcar-17 (Oxcar 17)

Illustration showing a hand shaking a bottle, indicating the proper way to prepare an oral suspension medication, such as Oxcarbazepine suspension, before use.*

FDA Label Image

Oxcar-18 (Oxcar 18)

Instructional illustration showing hands opening a bottle by squeezing the cap, indicating how to remove or break a safety seal from the bottle neck. The bottle and its separate cap are clearly visible.*

FDA Label Image

Oxcar-19 (Oxcar 19)

An instructional illustration depicting a hand shaking an oral suspension bottle, intended to demonstrate proper mixing before administration.*

FDA Label Image

Oxcar-20 (Oxcar 20)

An instructional line drawing showing a hand using a syringe to extract suspension medicine from a bottle. The syringe is inserted into the bottle’s opening, with an arrow indicating downward pressure for drawing the liquid.*

FDA Label Image

Oxcar-21 (Oxcar 21)

Illustration showing hands preparing an oral suspension medication using a bottle and a dosing syringe. The image depicts drawing medicine into the syringe from the bottle, indicated by a double-headed vertical arrow suggesting an up-and-down motion.*

FDA Label Image

Oxcar-22 (Oxcar 22)

An instructional illustration showing the correct technique for drawing oral suspension from a bottle using a dosing syringe. The image depicts a hand holding the bottle upside down while the other hand pulls the syringe plunger to measure the dose. A zoomed-in inset shows the syringe graduated in milliliters, highlighting the dosing scale from 0 to 10 mL.*

FDA Label Image

Oxcar-23 (Oxcar 23)

An instructional diagram showing a hand inserting and turning a dosing syringe to draw medication from a bottle, demonstrating the proper method for extracting oral suspension from the container.*

FDA Label Image

Oxcar-24 (Oxcar 24)

An instructional illustration showing a person administering Oxcarbazepine oral suspension by using an oral syringe to measure and give the medication, and an additional close-up of the syringe being filled from a cup. The images depict the proper method for measuring and dosing the suspension orally.*

FDA Label Image

Oxcar-26 (Oxcar 26)

Label for Oxcarbazepine Oral Suspension USP 300 mg/5 mL in a 250 mL bottle. The label highlights shake well before use instructions, dosage directions referring to the package insert, storage temperature guidelines, and warnings to keep out of children's reach. It is distributed by Marlex Pharmaceuticals, Inc and manufactured by Medley Pharmaceuticals Ltd in India for Kanchan Healthcare Inc in New Jersey.*

FDA Label Image

Oxcar-4 (Oxcar 4)

A data table presenting adverse reaction percentages by body system for Oxcarbazepine at daily doses of 2400 mg and 300 mg, with a sample size of 86 patients each. The table categorizes reactions such as fatigue, nausea, headache, dizziness, infections, respiratory symptoms, and others, showing higher percentages generally at the 2400 mg dose compared to the 300 mg dose.*

FDA Label Image

Oxcarb-10 (Oxcarb 10)

A Kaplan-Meier curve graph depicting the seizure rate over time in days from the first dose for two treatment groups: Oxcarbazepine oral suspension and placebo. The graph shows seizure incidence with statistical testing results, including a log-rank test p-value.*

FDA Label Image

Oxcarb-11 (Oxcarb 11)

A Kaplan-Meier survival curve chart comparing exit rates over time in days between two treatment groups labeled as HIGH and LOW. The y-axis represents the exit rate, and the x-axis shows time to exit in days. The chart includes a log-rank test p-value of 0.0001 indicating statistical comparison between the two groups.*

FDA Label Image

Oxcarb-13 (Oxcarb 13)

A data table showing results from two clinical trials (pediatrics and adults) for oxcarbazepine treatment groups versus placebo. Columns include trial number, treatment group details, sample size (N), baseline seizure rate, median seizure rate, and median percentage reduction in seizures.*

FDA Label Image

Oxcarb-8 (Oxcarb 8)

A data table presenting the influence of oxcarbazepine doses on concentrations of various coadministered antiepileptic drugs (AEDs) and their effects on MHD concentration. The table includes AED names, dose ranges, oxcarbazepine dose, mean changes in AED concentration with confidence intervals, and corresponding changes in MHD concentration with confidence intervals.*

FDA Label Image

Oxcarbazepine-9 (Oxcarb 9)

A Kaplan-Meier survival curve chart showing exit rates over time (days) from Day 2 to Day 11 for two treatment groups: Oxcarbazepine and Placebo. The Y-axis represents the exit rate from 0 to 1.0, and the X-axis represents the time on trial in days. The chart includes a log-rank test p-value of 0.0001 indicating statistical comparison between groups.*

FDA Label Image

Oxcarbazepine-fig1 (Oxcarbazepine 1)

A dosing chart presenting Oxcarbazepine oral suspension dosage ranges in mg/day based on patient weight in kilograms. The table lists weight increments from 20 to 70 kg, alongside corresponding from and to dose ranges (600 to 1500 mg/day starting doses and up to 2100 mg/day maximum doses).*

FDA Label Image

Oxcarbazepine-2 (Oxcarbazepine 2)

A data table comparing adverse event incidence rates per 1,000 patients between placebo and drug patients for epilepsy, psychiatric, and other categories. It includes columns for placebo patients with events, drug patients with events, relative risk, and risk difference, summarizing total event rates across these categories.*

FDA Label Image

Oxcarbazepine-25 (Oxcarbazepine 25)

Packaging label for Oxcarbazepine Oral Suspension, USP 300 mg/5 mL, an oral suspension in a 250 mL bottle. The label includes storage instructions, usage directions, and manufacturer information. It is distributed by Marlex Pharmaceuticals, Inc and manufactured by Medley Pharmaceuticals Ltd in India. The label features the Marlex Pharmaceuticals logo and emphasizes pharmacist instructions to dispense the enclosed Medication Guide.*

FDA Label Image

Oxcarbaepine-3 (Oxcarbazepine 3)

A data table showing the incidence of adverse reactions by body system for Oxcarbazepine at dosages of 600 mg, 1200 mg, and 2400 mg per day compared to placebo. Reactions are categorized by body system including body as a whole, cardiovascular, digestive, metabolic, musculoskeletal, nervous system, respiratory, skin, and special senses, with percentages of patients experiencing each reaction.*

FDA Label Image

Oxcarbazepine-5 (Oxcarbazepine 5)

A data table presenting adverse reactions by body system for Oxcarbazepine compared to placebo. It shows the percentage of patients experiencing various side effects such as nausea, dizziness, headache, and respiratory infections, with corresponding values for Oxcarbazepine (N=55) and placebo (N=49).*

FDA Label Image

Oxcarbazepine-6 (Oxcarbazepine 6)

A data table comparing the percentage of adverse reactions reported for Oxcarbazepine versus placebo. The adverse reactions are categorized by body system including body as a whole, digestive, nervous, respiratory, skin and appendages, and special senses, listing events such as fatigue, vomiting, headache, rhinitis, bruising, and diplopia.*

FDA Label Image

Oxcarbazepine-7 (Oxcarbazepine 7)

Chemical structure of oxcarbazepine, showing its molecular formula with a ketone group attached to a dibenzazepine ring system and an amidic substitution on the nitrogen atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.